
This document is important and requires your immediate attention. If you are in doubt as to the action you should take you should seek advice from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser. If you have sold or transferred all of your shares in the PIMCO StocksPLUS™ AR Fund* of PIMCO Funds: Global Investors Series plc, please pass this document at once to the stockbroker, bank or other agent through whom the sale or transfer was effected, for transmission to the purchaser or transferee as soon as possible. The Directors of PIMCO Funds: Global Investors Series plc are the persons responsible for the information contained in this document. All terms used in this document have the same meanings as in the Prospectus. Please note that this document is not reviewed by the Central Bank of Ireland.

CIRCULAR TO SHAREHOLDERS OF THE

PIMCO StocksPLUS™ AR Fund

a sub-fund of

PIMCO Funds: Global Investors Series plc

(An open-ended umbrella type investment company with variable capital and with segregated liability between Funds incorporated with limited liability in Ireland under the Companies Act 2014 with registered number 276928 and established as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011, as amended).

NOTICE CONVENING AN EXTRAORDINARY GENERAL MEETING TO BE HELD ON 28 AUGUST, 2026 AS SET OUT IN APPENDIX I. YOU ARE REQUESTED TO COMPLETE AND RETURN THE RELEVANT FORM OF PROXY SET OUT IN APPENDIX II IN ACCORDANCE WITH THE INSTRUCTIONS PRINTED THEREON.

FORMS OF PROXY ARE SET OUT IN APPENDIX II AND SHOULD BE RETURNED NO LATER THAN 48 HOURS BEFORE THE TIME FIXED FOR THE HOLDING OF THE EXTRAORDINARY GENERAL MEETING TO:

**Anthony Finegan,
Company Secretarial Team,
Walkers,
5th Floor, the Exchange,
George's Dock, IFSC, Dublin 1, Ireland
or
by email to Cosec@walkersglobal.com**

*Trademark of Pacific Investment Management Company LLC in the United States.

PIMCO Funds: Global Investors Series plc (the “Company”)

PIMCO StocksPLUS™ AR Fund (the “Fund”)

13 August, 2026

Dear Registered Shareholder,

1. Introduction

As you are aware, the Company is an investment company with variable capital and with segregated liability between funds, incorporated with limited liability under the laws of Ireland, authorised on 28 January, 1998 by the Central Bank of Ireland (the “**Central Bank**”) pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended (the “**Regulations**”).

The Directors of the Company wish to convene an Extraordinary General Meeting of the Fund on 28 August, 2026, at which investors will be asked to approve a change to the investment policy, as outlined in section 2 below and as further shown in **Appendix III**.

2. Overview of main amendments

Requiring Shareholder Approval

As you are aware, in seeking to achieve the Fund’s investment objective, the Fund follows the Investment Advisor’s proprietary portfolio management strategy known as “StocksPLUS” (which combines an actively managed portfolio of Fixed Income Instruments with exposure to equity securities). In accordance with the “StocksPLUS” portfolio management strategy, rather than buying physical stocks as traditional equity strategies do, the Fund invests under normal circumstances in derivatives (such as futures and total return swaps) that provide exposure to equities

The Fund’s indirect exposure to equities is currently to S&P 500 companies. However, the Company is proposing that this change to large/medium cap European companies.

Shareholder Notification

Subject to your approval of the above change to the investment policy and the requirements of the Central Bank, we hereby wish to notify you of the additional non-material amendments, including:

- the Fund is to be renamed the “PIMCO StocksPLUS™ Europe Fund”;
- the average portfolio duration will be lowered to “0-1 year”;
- the credit quality will be lowered from 20% max to 10% max below Baa;
- the index used by the Fund to measure performance and global exposure will change to the “*MSCI Europe Net Return Index*” for consistency with the Fund’s equity exposure change;

- the expected leverage range of the Fund will be lowered to 0% - 600% of Net Asset Value;
- the emerging markets limit will be lowered from 25% to 10%;
- the investment policy of the Fund is to be modified to provide for the promotion of environmental and social characteristics. Following the implementation of the change, the Fund will be categorised as an Article 8 Fund for the purposes of the SFDR (currently it is categorised as Article 6). Disclosure has been included in the updated Supplement and a pre-contractual Annex has been appended to the Supplement to reflect the new sustainability features of the Fund; and
- the Fund's base currency will transition from USD to Euro.

Fee reduction

There will be a reduction in fees for all share classes.

3. Fees and Expenses

The fees and expenses that will be incurred in connection with the changes to the Fund (including legal and administrative costs of drafting and implementing the proposed change to the Fund Supplement) will be borne by the Company's manager, PIMCO Global Advisors (Ireland) Limited.

4. Shareholders' Approval

For the sanctioning of the resolution to approve the proposed amendments (set out in Appendix III), subject to the requirements of the Central Bank, the Registered Shareholder of the Fund must pass the ordinary resolution (consisting of fifty-one per cent (51%) or more of the total number of votes cast).

The quorum for the Extraordinary General Meeting is two Registered Shareholders present (in person or by proxy). If within half an hour from the time appointed for the Extraordinary General Meeting, a quorum is not present, it shall be adjourned to the same day in the next week, at the same time and place or to such other day and at such other time and place as the Directors may determine.

If you are a registered holder of Shares in the Fund, you will receive a proxy form with this Circular. Please read the notes printed on the form, which will assist you in completing the proxy form, and return the proxy form to us. **To be valid, your appointment of proxy must be received no later than 48 hours before the time appointed for the Extraordinary General Meeting and therefore by 1 p.m. on 26 August, 2026 at the latest.**

The proposed effective date of the changes to the Fund will be on or around 11 September, 2026, subject to Shareholder approval of the proposed amendments and the requisite regulatory approvals, with the results of the Extraordinary General Meeting and the exact effective date to be made available from the Administrator, upon request.

5. Recommendation

The Directors believe that the proposed resolution is in the best interests of the investors of the Fund and therefore recommend that you vote in favour of the proposal. **Should you be in any doubt as to the actions you should take, we recommend that you consult with your own tax and legal advisers.**

6. Notice and Proxy Forms

Details of the specific resolution which the Registered Shareholder will be asked to approve is detailed in the Notice and Proxy Forms attached to this Circular.

This Circular is accompanied by the following documents:

1. Notice of the Extraordinary General Meeting of the Fund to be held at 1 p.m. on 28 August, 2026 at the offices of Walkers Corporate Services (Ireland) Limited, The Exchange, George's Dock, IFSC, Dublin 1, D01 W3P9, Ireland (Appendix I);
2. A Proxy Form which allows you to cast your vote by proxy (Appendix II);
3. Appendix III highlighting the amendments to the Fund Supplement.

In order to exercise your vote, please complete the attached Proxy Form and return it to:

Anthony Finegan,
Company Secretarial Team,
Walkers,
5th Floor, the Exchange,
George's Dock, IFSC, Dublin 1, Ireland

To be valid, the proxy forms must be received at the above address or by email to Cosec@walkersglobal.com no later than 48 hours before the time fixed for the holding of the Extraordinary General Meeting.

For any questions regarding this matter, investors may consult their financial adviser, the Company's appointed representative in that country or the Administrator. The Administrator may be contacted via e-mail at PIMCOEMteam@StateStreet.com, or by telephone as follows:

EMEA: +353 1 776 9990
Hong Kong: +852 35561498
Taiwan: +886 80 113 6992
Singapore: +65 68267589
Americas: +1 416 5068337

Yours faithfully,

A handwritten signature in dark ink, appearing to be 'R. J. H.', is written above a horizontal line.

Director

For and on behalf of PIMCO Funds: Global Investors Series plc

Information for investors in Switzerland:

The representative and paying agent of the Company in Switzerland is BNP PARIBAS, Paris, Zurich branch, Selnaustrasse 16, 8002 Zurich, Switzerland. The Prospectus, the Key Information Documents, the Memorandum and Articles of Association and the annual and semi-annual reports may be obtained free of charge from the Representative in Switzerland. In respect of the Shares proposed in Switzerland, the place of performance is at the registered office of the representative in Switzerland while the place of jurisdiction is at the registered office of the representative in Switzerland or at the seat/domicile of the investor.

APPENDIX I

NOTICE OF EXTRAORDINARY GENERAL MEETING

PIMCO Funds: Global Investors plc (the “Company”)

PIMCO StocksPLUS™ AR Fund (the “Fund”)

NOTICE IS HEREBY GIVEN that the Extraordinary General Meeting of the Registered Shareholder of the Fund will be held at the offices of Walkers Corporate Services (Ireland) Limited, The Exchange, George's Dock, IFSC, Dublin 1, D01 W3P9, Ireland on 28 August, 2026 at 1 p.m. for the following purposes:

1. To approve the change to the investment policy as highlighted in Appendix III.



For and on behalf of
Walkers Corporate Services (Ireland) Limited
Secretary
Dated this 13th day of August, 2026

Note: An investor entitled to attend and vote at the above Extraordinary General Meeting is entitled to appoint a proxy or proxies to attend and vote in his/her stead. A proxy need not be an investor.

APPENDIX II

PROXY FORM

**PIMCO Funds: Global Investors Series plc
(the “Company”)**

**PIMCO StocksPLUS™ AR Fund
(the “Fund”)**

I/We* _____

of _____

being an investor/investors* of the above named Fund hereby appoint the Chairman or, failing him/her, Anthony Finegan, Gabrielle Llamas, and/or Divine Ighodaro, or failing him/her any other representative of Walkers Corporate Services (Ireland) Limited or, failing him/her,

_____ of _____

as my/our* proxy to vote on my/our* behalf in the manner indicated below at the Extraordinary General Meeting of the Fund to be held at the offices of Walkers Corporate Services (Ireland) Limited, The Exchange, George's Dock, IFSC, Dublin 1, D01 W3P9, Ireland on 28 August, 2026 at 1 p.m. and at any adjournment thereof.

Signed _____

Dated this ____ day of _____, 2026

(*delete as appropriate)

RESOLUTION

For/Yes

Against/No

1. To approve the change to the investment policy as highlighted in Appendix III to the Shareholder Circular.		
---	--	--

Notes to Form of Proxy

1. Two Shareholders present in person or by proxy entitled to vote shall be a quorum for all purposes. If within half an hour from the time appointed for the annual general meeting, a quorum is not present, it shall be adjourned to the same day in the next week, at the same time and place or to such other day and at such other time and place as the Directors may determine. A Shareholder entitled to attend and vote at any such adjourned meeting is entitled to appoint a proxy to attend, speak and vote in his place and that a proxy need not be a Shareholder of the Company. This notice shall be deemed to constitute due notice of any such adjourned meeting within the meaning of the Articles.
2. A Shareholder may appoint a proxy of his own choice. If the appointment is made, insert the name of the person appointed as proxy in the space provided. A person appointed to act as a proxy need not be a Shareholder.
3. If the appointer is a corporation, this form must be under the common seal or under the hand of an officer or attorney duly authorised on his behalf. Please note that only authorised signatories as per the authorised signatory list on file at the offices of the Administrator may sign this form.
4. In the case of joint Shareholders, the signature of any one Shareholder will be sufficient, but the names of all the joint Shareholders should be stated. Please note that only authorised signatories as per the authorised signatory list on file at the offices of the Administrator may sign this form.
5. If this form is returned without any indication as to how the person appointed proxy shall vote he will exercise his discretion as to how he votes or whether he abstains from voting.
6. To be valid, this form must be completed and deposited by mail or by email for the attention of Anthony Finegan, Walkers Corporate Services (Ireland) Limited, The Exchange, George's Dock, IFSC, Dublin 1, D01 W3P9, Ireland or sent to the email address of cosec@walkersglobal.com, not less than 48 hours before the time fixed for holding the annual general meeting or adjourned meeting.
7. To any investor in receipt of this circular who is not on the Shareholder register for the relevant Fund of the Company please return the completed proxy forms to the financial intermediary who purchased Shares in the relevant Fund of the Company on your behalf.
8. If you have any questions regarding the information provided in this circular please contact PIMCO Shareholder Services at the following numbers: EMEA: +353 1 776 9990, Hong Kong: +852 35561498, Singapore: +65 68267589, Taiwan: 00801136992, Americas: +1 416 5068337. Alternatively, you may contact us by email at: PIMCOEMteam@StateStreet.com.

APPENDIX III

AMENDMENTS TO THE FUND SUPPLEMENT WITH REGARD TO THE INVESTMENT OBJECTIVE AND CERTAIN RELATED CHANGES TO THE INVESTMENT POLICY

PIMCO Funds: Global Investors Series plc
(the “Company”)

PIMCO StocksPLUS™ AR Fund
(the “Fund”)

Please find below the relevant extract from the PIMCO StocksPLUS™ AR Fund Supplement, highlighting the deletions by strike through and additions by underling of the proposed amendment thereto:

Investment Objective and Policies

In accordance with the “StocksPLUS” portfolio management strategy, rather than buying physical stocks as traditional equity strategies do, the Fund invests under normal circumstances in derivatives (such as futures and total return swaps) that provide exposure to equities of ~~US large capitalisation~~ European large or medium capitalisation companies. Derivatives can be purchased with a fraction of the capital that would be needed to purchase the equity securities directly and therefore the remaining assets can be invested in Fixed Income Instruments. The notional portfolio of equity securities that the Fund gains exposure to is selected to provide a broad diversified exposure to US European equity markets. The underlying stocks are selected from these equity markets based on their market capitalisation. Stocks are then weighted based on their market capitalisation and the Fund’s exposure will be taken primarily to equities issued by companies with a large or medium market capitalisation. ~~The Fund will take exposure to, approximately, the five hundred largest companies (i.e. companies with large market capitalization) within US~~ within European equity markets.

As outlined above, the Fund will utilise derivative instruments on a notional portfolio of equity securities, primarily swaps and futures (which may be listed or over-the-counter) that provide exposure to US European equities. Swaps will be used for the Fund to seek exposure to the notional portfolio of equity securities equivalent to approximately 100% of the Fund’s net asset value. In a typical swap agreement, the Fund will receive some or all of the price appreciation (or depreciation) of the equity security or equity securities from the counterparty to the swap agreement in exchange for paying the counterparty an agreed fee. Further information in relation to swaps and derivatives is outlined below.

*Subject to the Regulations as set forth in **Appendix 3** and as more fully described under the headings “**Efficient Portfolio Management and Securities Financing Transactions**” and “**Characteristics and Risks of Securities, Derivatives, Other Investments and Investment Techniques**”, the Fund may use equity-related and fixed income-related derivative instruments, including futures, swaps, options (including barrier options), options on futures and may also enter into currency forward contracts. Swaps (including Total Return Swaps, interest rate swaps, credit default swaps and variance/volatility swaps) used by the Fund will be based on asset classes contemplated under the investment policy of the Fund as set out herein in addition to permissible indices, currencies and interest rates. Such derivative instruments may be used (i) for hedging purposes and/or (ii) for investment purposes and/or (iii) efficient portfolio management purposes. For example, the Fund may use derivatives (~~which will be based only on underlying assets or indices based on equity, equity-related and Fixed Income Securities which are permitted under the investment policy of the Fund~~) (i) to hedge a currency exposure, (ii) as a substitute for taking a position in the underlying asset where the Investment Advisor feels that a derivative exposure to the underlying asset represents better value than a direct exposure, (iii) to tailor the Fund’s exposures to the Investment Advisor’s outlook for various markets, and/or (iv) as per the Fund’s investment policy to gain exposure to US European equities. Details of any financial indices used by the Fund will be provided to Shareholders by the Investment Advisor on request and will be set out in the Company’s semi-annual and annual accounts. Further information is set out in the Prospectus under the heading “**Financial Indices**”. Any such indices will be used in accordance with the requirements of the Central Bank. Only derivative instruments listed in the Company’s risk management process as prepared and submitted to the Central Bank in accordance with the Central Bank*

requirements may be utilised. In respect of any instrument which contains an embedded derivative, the derivative component of such instrument shall be of a type which the Fund could otherwise invest in directly.

The Fund intends to use the Relative VaR model. Accordingly, the VaR of the Fund's portfolio will not exceed twice the VaR on a comparable benchmark portfolio which will reflect the Fund's intended investment style. The benchmark portfolio will be the Index. The Index ~~is composed of 500 selected common stocks, most of which are listed in the New York Stock Exchange~~ captures large and mid cap representation across 15 developed markets countries in Europe. Further details on the Index are publicly available or from the Investment Advisor upon request. The holding period shall be 20 days. The historical observation period shall not be less than one year. It should be noted that the above limits are the current VaR limits required by the Central Bank. However, should the VaR model for the Fund or the Central Bank limits change, the Fund will have the ability to avail of such new model or limits by updating this Supplement and the Risk Management Process of the Company accordingly. The measurement and monitoring of all exposures relating to the use of derivative instruments will be performed on at least a daily basis.